This activity has been planned for clinicians who treat lung cancer patients: knowing how COVID-19 alters physiology is crucial to providing care that will ameliorate infection symptoms while not exacerbating lung cancer symptoms. Further, clinicians must be aware of factors that increase these patients’ risk for COVID-19 infection, including decreased immunity due to pharmacotherapy and abnormal anatomy and cellular structure after surgery and/or radiation therapy.

DATES AND TIMES
Tuesday, September 29, 2020
1:00 – 2:00 PM ET (5:00 – 6:00 PM GMT / 12:00 Noon – 1:00 PM CT / 10:00 – 11:00 AM PT)

Thursday, October 15, 2020
7:00 – 8:00 PM ET (11:00 PM – 12:00 AM GMT / 6:00 – 7:00 PM CT / 4:00 – 5:00 PM PT)

AGENDA
Welcome and Introduction
Understanding the Pathophysiology of COVID-19
Recognizing the Risk of COVID-19 in Patients with Lung Cancer
Managing Patients with Lung Cancer During the COVID-19 Pandemic

Q&A Session and Concluding Remarks


PROGRAM DESCRIPTION
Patients with underlying health conditions such as lung cancer are at greater risk for infection or complications from COVID-19. Because of this increased risk, it is important that these patients are carefully managed, with telemedicine replacing in-person visits where possible. However, monitoring patients via telemedicine requires special attention, particularly because symptoms of COVID-19 infection are similar to common adverse events associated with lung cancer treatment.

This activity, “Lung Cancer and COVID-19 in the Outpatient Setting: What Clinicians Need to Know” will provide clinicians with the most up-to-date guidance on managing lung cancer during the current pandemic, including information on the pathophysiology of Sars-Cov-2, the risk of infection in patients with lung cancer, and strategies to manage patient care and counsel through telemedicine.